Longevity News

Valgen Medtech

Source: PR Newswire • Published: 24 Jun 2026, 07:00

Valgen Medtech

Look at a transcatheter mitral valve repair technology advancing treatment for functional mitral regurgitation and global clinical adoption.

Key Takeaways
  • Device received CE mark approval in the EU for functional mitral regurgitation
  • One-year data showed 86.7% achieved the composite primary effectiveness endpoint
  • Procedural and device implantation success rates reached 97.4% in the pivotal study
Read Original Source